27 results
6-K
EX-99.1
IFRX
InflaRx N.V.
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
Exhibit 99.1
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
Thomas Taapken, Ph.D … , and is an ideal fit as we advance our late-stage clinical development programs. Thomas has proven great leadership capabilities and is an excellent
6-K
EX-99.3
IFRX
InflaRx N.V.
29 Oct 20
Current report (foreign)
7:05am
Announced leadership team additions
Cash, cash equivalents and financial assets of approximately €95.7 million as of September 30, 2020
Jena, Germany … .”
Corporate and R&D Highlights
Leadership appointments: In September 2020, InflaRx announced the appointment of Thomas Taapken, Ph.D. as Chief Financial
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Sep 18
InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors
8:38am
. Holstein brings with him in depth industry experience through numerous financial leadership positions he held in both biotech and healthcare over
6-K
EX-99.1
IFRX
InflaRx N.V.
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
and finance can provide incremental support to our strong Board of Directors and deep leadership team at InflaRx, as we look forward to multiple value
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development
6-K
EX-99.3
qdbab mwf994lpy6pmyo
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.3
ndi4bv5wp udsq
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
6iozzju4
8 May 19
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019
6:02am
6-K
EX-99.2
jpkeidf
5 Aug 21
Current report (foreign)
8:23am
424B5
409p7
20 Jul 20
Prospectus supplement for primary offering
9:21am
424B5
x71po9eee hgh
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
d3gp9
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
1gj5 2jxw32c7k0d
8 Jul 20
Shelf registration (foreign)
12:00am
424B5
0y5ao
11 Apr 23
Prospectus supplement for primary offering
4:11pm
424B5
d8jh9gvse749dizfx
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
2685el a9gygxn41
24 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
4p1t 3lcr24
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B4
zy1algs20
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
qbzlmrin
2 May 18
Registration statement (foreign)
7:10am